Trial Profile
Biomarker as Predicting Response to Sunitinib in Metastatic Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 May 2018
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- 08 May 2018 New trial record
- 01 May 2018 Results published in the Anticancer Research